{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:15:45Z","timestamp":1793844945981,"version":"4.6.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.genhosppsych.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:05:55Z","timestamp":1657800355000},"page":"58-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis"],"prefix":"10.1016","volume":"78","author":[{"given":"Kenn","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seri","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cleaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","article-title":"Excess early mortality in schizophrenia","volume":"10","author":"Laursen","year":"2014","journal-title":"Annu Rev Clin Psychol"},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.24869\/psyd.2017.108","article-title":"Causes of mortality in schizophrenia: an updated review of European studies","volume":"29","author":"Piotrowski","year":"2017","journal-title":"Psychiatr Danub"},{"issue":"3","key":"10.1016\/j.genhosppsych.2022.07.006_bb0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/schbul\/sbu138","article-title":"Mortality in schizophrenia and other psychoses: a 10-year follow-up of the \u04d4SOP first-episode cohort","volume":"41","author":"Reininghaus","year":"2015","journal-title":"Schizophr Bull"},{"issue":"4","key":"10.1016\/j.genhosppsych.2022.07.006_bb0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0025","series-title":"Schizophrenia [Internet]","author":"World Health Organization","year":"2022"},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"GBD","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.genhosppsych.2022.07.006_bb0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpsychires.2018.04.019","article-title":"Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis","volume":"102","author":"Oakley","year":"2018","journal-title":"J Psychiatr Res"},{"issue":"10","key":"10.1016\/j.genhosppsych.2022.07.006_bb0045","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.genhosppsych.2022.07.006_bb0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/YCO.0000000000000530","article-title":"Causes of premature mortality in schizophrenia: a review of literature published in 2018","volume":"32","author":"Laursen","year":"2019","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0060","first-page":"20170065","article-title":"Cardiometabolic effects of psychotropic medications","volume":"36","author":"Abosi","year":"2018","journal-title":"Horm Mol Biol Clin Invest"},{"issue":"11","key":"10.1016\/j.genhosppsych.2022.07.006_bb0065","article-title":"Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness","author":"Mazereel","year":"2020","journal-title":"Front Endocrinol"},{"issue":"13","key":"10.1016\/j.genhosppsych.2022.07.006_bb0070","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1017\/S0033291717000873","article-title":"Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis","volume":"47","author":"Vermeulen","year":"2017","journal-title":"Psychol Med"},{"issue":"9","key":"10.1016\/j.genhosppsych.2022.07.006_bb0075","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1176\/appi.ps.201500061","article-title":"Trends in use and cost of second-generation antipsychotics among children and teens in Indiana Medicaid, 2004\u20132012","volume":"67","author":"Goddard","year":"2016","journal-title":"PS."},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1176\/appi.ps.201100092","article-title":"Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998\u20132009","volume":"63","author":"Pillarella","year":"2012","journal-title":"PS."},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0085","doi-asserted-by":"crossref","first-page":"17m11970","DOI":"10.4088\/JCP.17m11970","article-title":"Antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: National Trends from 2006 to 2015","volume":"79","author":"Rhee","year":"2018","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.genhosppsych.2022.07.006_bb0090","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1176\/appi.ajp.2020.19091000","article-title":"20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings","volume":"177","author":"Rhee","year":"2020","journal-title":"AJP."},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0100","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ."},{"issue":"12","key":"10.1016\/j.genhosppsych.2022.07.006_bb0105","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2009.07.031","article-title":"Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome","volume":"314","author":"Maury","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"10.1016\/j.genhosppsych.2022.07.006_bb0115","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1161\/CIRCRESAHA.114.302699","article-title":"Inflammation and its resolution as determinants of acute coronary syndromes","volume":"114","author":"Libby","year":"2014","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.genhosppsych.2022.07.006_bb0120","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.metabol.2013.07.001","article-title":"Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance","volume":"62","author":"Aroor","year":"2013","journal-title":"Metabolism."},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuropharm.2015.04.011","article-title":"Histamine receptor signaling in energy homeostasis","volume":"106","author":"Tabarean","year":"2016","journal-title":"Neuropharmacology."},{"issue":"5","key":"10.1016\/j.genhosppsych.2022.07.006_bb0130","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cmet.2007.10.008","article-title":"Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways","volume":"6","author":"Zhou","year":"2007","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors. Sibley DR, editor","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.genhosppsych.2022.07.006_bb0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ph14030238","article-title":"Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences","volume":"14","author":"Carli","year":"2021","journal-title":"Pharmaceuticals."},{"issue":"6","key":"10.1016\/j.genhosppsych.2022.07.006_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. Gaetani S, editor","volume":"6","author":"Fern\u00f8","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0150","series-title":"The Five Year Forward View for Mental Health [Internet]","author":"Mental Health Taskforce","year":"2016"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0155","series-title":"Commissioning for Quality and Innovation (CQUIN) Guidance for 2017-2019 [Internet]","author":"NHS England","year":"2018"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0160","series-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia [Internet]. Third Edition. American Psychiatric Association Publishing","author":"American Psychiatric Association","year":"2020"},{"issue":"8","key":"10.1016\/j.genhosppsych.2022.07.006_bb0165","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0170","series-title":"The Maudsley Practice Guidelines for Physical Health Conditions in Psychiatry","first-page":"125","article-title":"Obesity","author":"Mizuno","year":"2020"},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0175","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","author":"Jensen","year":"2014","journal-title":"Circulation [Internet]"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0185","series-title":"Obesity: Identification, assessment and management of overweight and obesity in children, young people and adults","author":"National Institute for Health and Care Excellence (Great Britain)","year":"2014"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0190","series-title":"Semaglutide for managing overweight and obesity [ID3850] (In development [GID-TA10765]) [Internet]","author":"National Institute for Health and Care Excellence (Great Britain)","year":"2022"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0195","first-page":"53","article-title":"The law and practice of off-label prescribing and physician promotion","volume":"49","author":"Syed","year":"2021","journal-title":"J Am Acad Psychiatry Law"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0200","series-title":"Good practice in prescribing and managing medicines and devices: prescribing unlicensed medicines [internet]","author":"General Medical Council","year":"2021"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0205","series-title":"British National Formulary [Internet]. (online)","author":"Joint Formulary Committee","year":"2022"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0210","author":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0215","author":"Lee"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0220","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0225","series-title":"FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market [Internet]","author":"Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0230","series-title":"The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia [internet]","author":"European Medicines Agency","year":"2008"},{"issue":"3","key":"10.1016\/j.genhosppsych.2022.07.006_bb0240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1348\/000712608X377117","article-title":"Standardized or simple effect size: what should be reported?","volume":"100","author":"Baguley","year":"2009","journal-title":"Br J Psychol"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0245","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 63 (updated February 2022) [Internet]. Cochrane","article-title":"Chapter 13: Assessing risk of bias due to missing results in a synthesis","author":"Page","year":"2022"},{"issue":"4","key":"10.1016\/j.genhosppsych.2022.07.006_bb0250","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0255","first-page":"282","article-title":"Liraglutide efficacy and tolerability in obese patients affected by severe psychiatric disorders. In: European Association for the Study of Obesity (2018) 25th European Congress on Obesity, Vienna, Austria, May 23\u201326, 2018: Abstracts","volume":"11","author":"Maccora","year":"2018","journal-title":"Obes Facts"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0260","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/S0924-977X(16)31091-4","article-title":"Liraglutide in psychiatric patients: preliminary results","volume":"26","author":"Di Volo","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.genhosppsych.2022.07.006_bb0265","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/j.biopsych.2022.02.411","article-title":"P177. Semaglutide to the rescue: real-world clinical data in patients with antipsychotic-induced weight gain not responding to metformin","volume":"91","author":"Prasad","year":"2022","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0270","author":"Yale University"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0275","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.orcp.2020.11.002","article-title":"The use of anti-obesity medications in people with mental illness as an adjunct to lifestyle interventions \u2014 effectiveness, tolerability and impact on eating behaviours: a 52-week observational study","volume":"15","author":"Tham","year":"2021","journal-title":"Obes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.genhosppsych.2022.07.006_bb0280","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.genhosppsych.2022.07.006_bb0285","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of Liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiat"},{"issue":"113830","key":"10.1016\/j.genhosppsych.2022.07.006_bb0290","article-title":"Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients","volume":"299","author":"Lee","year":"2021","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0295","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4158\/EP-2019-0169","article-title":"One month weight loss predicts the efficacy of Liraglutide in obese patients: data from a single center","volume":"26","author":"Maccora","year":"2020","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"10.1016\/j.genhosppsych.2022.07.006_bb0305","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fphar.2018.00181","article-title":"Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia","author":"Lyu","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.genhosppsych.2022.07.006_bb0310","series-title":"Mysimba 8 mg\/90 mg prolonged-release tablets - Summary of Product Characteristics (SmPC) [Internet]","author":"European Medicines Agency","year":"2021"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17512433.2020.1698291","article-title":"Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs","volume":"13","author":"Singh","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0320","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1467-789X.2004.00131.x","article-title":"Smoking cessation and weight gain","volume":"5","author":"Filozof","year":"2004","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.genhosppsych.2022.07.006_bb0325","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"de Silva","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0330","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial: ISH\u00d8Y et al","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.genhosppsych.2022.07.006_bb0335","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834322000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834322000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:53:50Z","timestamp":1759013630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834322000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":66,"alternative-id":["S0163834322000895"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2022.07.006","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}